Page 173 - EJMO-9-2

Eurasian Journal of
Medicine and Oncology Genetic insights into CAD drug targets

on the progression of CA. Special attention should be Ethics approval and consent to participate
given to observing the effects of targeted therapies in
mouse models This research utilized publicly accessible data. Each
(ii) Diverse population validation: Researchers could study within the GWAS was approved by the appropriate
perform validation studies across different ethnicities, Institutional Review Board, and the participants or their
genders, and clinical subtypes to ensure that these authorized representatives provided informed consent.
drug targets have universal applicability and specific Consent for publication
effects for diverse populations
(iii) Clinical trials: Researchers could initiate early-stage Not applicable.
clinical trials that target candidate drug targets to
assess drug efficacy and dose response, particularly Availability of data
regarding the application of artemisinin and lovastatin The datasets analyzed during the current study are available
in CA. Long-term follow-up studies are crucial to in the following repositories: eQTLs data were obtained from
evaluate the efficacy and safety of these drugs, as well eQTLGen consortium (https://eqtlgen.org/); CA discovery
as their long-term clinical benefits in CA. data were from a previous study and downloaded on GWAS
Catalog (https://www.ebi.ac.uk/gwas/); CA replication data
5. Conclusion were from FinnGen Release 8 (https://www.finngen.fi/en);

Our study identified nine potential drug targets related and UK Biobank (https://www.ukbiobank.ac.uk/).
to CA through MR analysis, with four targets further
supported by colocalization analysis. GO enrichment References
analysis indicated that these genes play an important role 1. Stone PH, Libby P, Boden WE. Fundamental pathobiology of
in regulating immune responses and metabolism. Besides, coronary atherosclerosis and clinical implications for chronic
PheWAS analysis revealed no significant association ischemic heart disease management-the plaque hypothesis:
between the DHX36 gene and other traits, suggesting its A narrative review. JAMA Cardiol. 2023;8(2):192-201.
specificity may facilitate targeted therapy. Drug prediction doi: 10.1001/jamacardio.2022.3926
and molecular docking verified the binding potential of 2. Shao C, Wang J, Tian J, Tang YD. Coronary artery disease:
multiple candidate drugs to these target genes, providing From mechanism to clinical practice. Adv Exp Med Biol.
promising targets for developing new CA treatments, 2020;1177:1-36.
potentially reducing drug development costs, and
promoting personalized therapies. Future research should doi: 10.1007/978-981-15-2517-9_1
further explore the biological functions of these targets and 3. Baaten C, Nagy M, Bergmeier W, Spronk HMH, van der
conduct drug development and clinical trials to validate Meijden PEJ. Platelet biology and function: Plaque erosion
their therapeutic effects. vs. rupture. Eur Heart J. 2024;45(1):18-31.

Acknowledgments doi: 10.1093/eurheartj/ehad720
4. Milutinovic A, Suput D, Zorc-Pleskovic R. Pathogenesis of
None. atherosclerosis in the tunica intima, media, and adventitia of

Funding coronary arteries: An updated review. Bosn J Basic Med Sci.
2020;20(1):21-30.
This study was supported by the Ningxia Natural Science doi: 10.17305/bjbms.2019.4320
Foundation (2021AAC03140).
5. Duggan JP, Peters AS, Trachiotis GD, Antevil JL.
Conflict of interest Epidemiology of coronary artery disease. Surg Clin North
Am. 2022;102(3):499-516.
The authors declare that they have no conflicts of interest.
doi: 10.1016/j.suc.2022.01.007
Author contributions 6. Gawaz M, Geisler T, Borst O. Current concepts and

Conceptualization: Yue Wang, Zhi-Na Liu novel targets for antiplatelet therapy. Nat Rev Cardiol.
2023;20(9):583-599.
Formal analysis: Tao Wang, Li-Ming Yan
Investigation: Yue Wang doi: 10.1038/s41569-023-00854-6
Methodology: Zhi-Na Liu 7. Eghtedari B, Roy SK, Budoff MJ. Anti-inflammatory
Writing – original draft: Li-Ming Yan therapeutics and coronary artery disease. Cardiol Rev.
Writing – review & editing: Tao Wang 2023;31(2):80-86.

Volume 9 Issue 2 (2025) 165 doi: 10.36922/ejmo.7387